CSEM develops a pioneering implant to support reproductive medicine

Swiss-based start-ups Impli and Yalosys, along with the technology innovation center CSEM, announce a significant milestone in women’s healthcare—CERES. This implantable biosensor for real-time fertility hormone monitoring is now set to undergo a transformation that will make it ready for human trials by 2025. With Impli’s expertise, the biosensor has matured from a concept to a tangible solution that currently tracks fertility hormones in real-time. CSEM’s and Yalosys will now provide the technological development to refine and enhance the biosensor’s capabilities.